Ocular Therapeutix (OCUL) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- -$0.35
- Estimate
- -$0.39
- Surprise
- +9.4%
- Revenue (period 2026-06-30)
- $13.5M
- Score today
- 4.2/10
Revenue source: xbrl.
How the report landed
Ocular Therapeutix (OCUL) reported a narrower loss than forecast — diluted EPS of -$0.35 against the -$0.39 estimate (a 9.4% beat on a still-unprofitable quarter).
Where TrendMatrix's rating stands now
TrendMatrix currently rates OCUL Sell at 4.2/10; no pre/post engine snapshot brackets this report.
2 of the last 4 quarters beat the estimate; this quarter's +9.4% surprise compares with a -3.5% four-quarter average. Next scheduled report: 2026-11-04.
What argues against it
- Concentration risk — Product: DEXTENZA
- Concentration risk — Pipeline: AXPAXLI
- Quality below floor (1.8 < 4.0)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $10.45
- Price target
- $23.57
- Stop
- $9.90
- Upside to target
- +125.6%
- Reward-to-risk
- 8.1:1
Model outputs from TrendMatrix’s engine as of 2026-09-06 — shown for context, not personalized investment advice.
OCUL at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $2.34B
- P/E (fwd)
- -7.3
- 52-week range
- $6.23–$16.44
- Off 52-week high
- 36.4%
- RSI (14)
- 50
- Volume vs avg
- 0.48×
- Score today
- 4.2/10